Cost-effectiveness analysis of natalizumab compared with other disease modifying treatments for people with highly active relapsing-remitting multiple sclerosis in the UK
Pharmacoeconomics 26(7)617-27
Authors: Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, et al
Year: 2008
Category: test1